

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 9/19/1993  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Dermatomyositis Autoantibody Panel**

ARUP test code 3001782

Mi-2 (nuclear helicase protein) Antibody	Negative	(Ref Interval: Negative)
P155/140 Antibody	Negative	(Ref Interval: Negative)
TIF-1 gamma (155 kDa) Ab	Negative	(Ref Interval: Negative)
SAE1 (SUMO activating enzyme) Ab	Negative	(Ref Interval: Negative)
MDA5 (CADM-140) Ab	Negative	(Ref Interval: Negative)
NXP2 (Nuclear matrix protein-2) Ab	Negative	(Ref Interval: Negative)
Dermatomyositis Interpretive Information	See Note	

**H=High, L=Low, \*=Abnormal, C=Critical**

**INTERPRETIVE INFORMATION: Dermatomyositis Autoantibody Panel**

If present, myositis-specific antibodies (MSA) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositis-associated antibodies (MAA) may be found in patients with CTD including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

Antibody Specificity . . . . .	MSA . . . . .	MAA
Mi-2 (nuclear helicase protein) Antibody . . . . .	X	
P155/140 Antibody . . . . .	X	
TIF-1 gamma (155 kDa) Ab . . . . .	X	
SAE1 (SUMO activating enzyme) Ab . . . . .	X	
MDA5 (CADM-140) Ab . . . . .	X	
NXP2 (Nuclear matrix protein-2) Ab . . . . .	X	

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**VERIFIED/REPORTED DATES**

Procedure	Accession	Collected	Received	Verified/Reported
Mi-2 (nuclear helicase protein) Antibody	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
P155/140 Antibody	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
TIF-1 gamma (155 kDa) Ab	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SAE1 (SUMO activating enzyme) Ab	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDA5 (CADM-140) Ab	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
NXP2 (Nuclear matrix protein-2) Ab	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Dermatomyositis Interpretive Information	22-278-400637	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

**END OF CHART**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at: